Strong growth of special medication in the vaccine …

• Group sale: 4% in the first quarter of 2025.

• Operating profit: Increased by 5%.

• Core profit per share: Rose 5% to GBP 0.449.

• Special medication sales: By 17%.

• Vaccination sale: 6%by 6%.

• Comed cash from the operations: Over 1 billion GBP.

• Dividend: Increased to 0.16 GBP per share.

• Shared reference program: GBP started 2 billion.

• Sales in Q1: GBP 7.5 billion, 4% compared to the previous year.

• Europe sales growth: By 11%.

• US sales growth: 4%.

• Oncology sales: 53%.

• HIV sales growth: Around 7%.

• Vaccination sale for Q1: Over 2 billion GBP, by 6%.

• General medical sales: Stable, with the sales of the airways by 1%.

• Core operating margin: Improves to 33.5%.

• Cash from operations (without Zantac payments): GBP 1.4 billion.

• Free Cashflow (without Zantac payments): Improved by GBP 0.5 billion.

• Royalty income for 2025: GBP 750 to 800 million GBP.

Appearance date: April 30, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• GSK PLC (NYSE: GSK) recorded an increase in group sales by 4% and an increase in operating profit by 5%, which demonstrates the strength and resilience of its portfolio.

• Special medications, the largest business segment, grew by 17%, which is due to strong performance in breathing, immunology, inflammation, oncology and HIV.

• The company has completed the acquisition of Idrx and expanded its pipeline a promising oncology assets.

• GSK PLC (NYSE: GSK) achieved a price of 1 billion GBP in cash and supports further investments in growth and shareholders.

• The company confirmed its financial guidelines for 2025, which indicates trust in the ongoing profitable growth.

• The vaccine turnover decreased by 6%, with the pace of penetration in the USA slowed down due to the high immunization rates.

• The introduction of inflation reduction act (IRA) is expected to be over 400 million GBP to 500 million GBP all year round.

• The sales of general medicine was largely stable, with some areas going back due to the generic competition.

• The macro environment shows an increased degree of uncertainty, including potential sector tariffs.

• The company faces challenges on the US vaccine market with potential effects on political rhetoric and regulatory hurdles.

Q: What do your expectations expect from the upcoming starts of Newuara COPD and GlenRep? Could there be a strong recording in H2 2025 or are they more stories in 2026? How can tariffs affect the GSK and how high are the mitigating strategies? A: (Dame Emma Walmsley, CEO) We look forward to the new starts. For Newuara COPD, PDUFA is on the right track on May 7th and we expect the doctor to be very interested. However, pulmonologists are generally conservative, so the recording can gradually be. For GlenRep, we are careful about the immediate contribution, since the side effects of eye systems have to be treated carefully. With regard to tariffs, we have prepared several strategies, including resilience and improving the productivity of the supply chain to reduce possible effects.